# The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension

> **NCT07261098** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shanghai Chest Hospital** · enrollment: 200 (estimated)

## Conditions studied

- Advanced Lung Cancer

## Interventions

- **DRUG:** ARNI
- **DRUG:** Anti-hypertensive drugs except ARNI

## Key facts

- **NCT ID:** NCT07261098
- **Lead sponsor:** Shanghai Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2025-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07261098

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07261098, "The Efficacy and Safety of ARNI on the Outcome of Advanced Lung Cancer With Concurrent Hypertension". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07261098. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*